Epstein–Barr virus: Dermatologic associations and implications

Eminger, Lindsay A.; Hall, Lawrence D.; Hesterman, Kathleen; Heymann, Warren R.

doi:10.1016/j.jaad.2014.07.035

Cited by 57 publications

(12 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most frequent manifestations of LyG include multiple, bilateral lung infiltrates or nodules in virtually all cases 167 . Skin involvement occurs in 40–50% of cases 85,171–175 . Other organs that are frequently involved include the kidneys, CNS and GI tract.…”

Section: Lymphomatoid Granulomatosis (Lyg)mentioning

confidence: 99%

Cutaneous EBV-related lymphoproliferative disorders

Gru

Jaffe

2017

Seminars in Diagnostic Pathology

View full text Add to dashboard Cite

This article will focus on the cutaneous lymphoproliferative disorders associated with EBV, with an emphasis on the upcoming changes in the revised 4th Edition of the WHO classification of tumors of the hematopoietic system, many of which deal with cutaneous disorders derived from NK-cells or T-cells. Extranodal NK/T-cell lymphoma usually presents in the upper aerodigestive tract, but can involve the skin secondarily. EBV-associated T- and NK-cell lymphoproliferative disorders (LPD) in the pediatric age group include the systemic diseases, chronic active EBV infection (CAEBV) and systemic EBV+ T-cell lymphoma of childhood. Hydroa vacciniforme (HV)-like LPD is a primarily cutaneous form of CAEBV and encompasses the lesions previously referred to as HV and HV-like lymphoma (HVLL). All the T/NK-cell-EBV-associated diseases occur with higher frequency in Asians, and indigenous populations from Central and South America and Mexico. Among the B-cell EBV-associated LPD two major changes have been introduced in the WHO. The previously designated EBV-positive diffuse large B-cell lymphoma (EBV-DLBCL) of the elderly, has been changed to EBV-DLBCL with 'not otherwise specified' as a modifier (NOS). A new addition to the WHO system is the more recently identified EBV+ mucocutaneous ulcer, which involves skin and mucosal-associated sites.

show abstract

Section: Lymphomatoid Granulomatosis (Lyg)mentioning

confidence: 99%

Cutaneous EBV-related lymphoproliferative disorders

Gru

Jaffe

2017

Seminars in Diagnostic Pathology

View full text Add to dashboard Cite

show abstract

“…15 The clinical presentations of primary cutaneous EBVpositive DLBCL are variable, ranging from a single nodule to multiple plaques. 16 An involvement of other organs should be investigated such as bone marrow, lungs, gastrointestinal tract, and ear, nose and throat (ENT) region. 17 Primary cutaneous EBV-positive DLBCL is diagnosed with a skin biopsy with or without an excisional biopsy of a suspicious lymph node, which always shows positivity for EBER through in situ hybridization analysis.…”

Section: Discussionmentioning

confidence: 99%

“…The clinical presentations of primary cutaneous EBV‐positive DLBCL are variable, ranging from a single nodule to multiple plaques 16 . An involvement of other organs should be investigated such as bone marrow, lungs, gastrointestinal tract, and ear, nose and throat (ENT) region 17 .…”

Section: Discussionmentioning

confidence: 99%

Multiple cutaneous ulcers revealing a primary cutaneous Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma

Tedbirt

Dubois

Cellier

et al. 2020

Clinical Case Reports

View full text Add to dashboard Cite

Primary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphoma (PC-EBV-DLBCL) is an exceptional and aggressive neoplasia with a poorer prognosis than other cutaneous lymphoma. This case highlights this immunosenescence-associated lymphoid malignancy as an edifying cause of multiple skin ulcerations, distinct from other leg ulcers unrelated to arterial and venous disease. Approximately, 20% of cutaneous lymphomas are B-lymphocyte-derived malignancies exclusively involving cutaneous site at the time of diagnosis. Cutaneous B-cell lymphomas (CBCL) are classified into five distinct subgroups: primary cutaneous follicle center lymphoma (PCFCL); primary cutaneous marginal zone lymphoma (PCMZL); primary cutaneous diffuse large B-cell lymphoma (PC-DLBCL), leg type; intravascular diffuse large B-cell lymphoma (IV-DLBCL); and DLBCL, not otherwise specified (NOS). The prognosis of CBCL may vary depending on the subtype of CBCL. PCMZL and PCFCL are indolent forms, whereas PCLBCL, leg type, and IV-DLBCL have an intermediate to aggressive clinical course. The 2016 revision of the World Health Organization (WHO) classification of lymphoid malignancies recognized primary cutaneous Epstein-Barr virus (EBV)-positive DLBCL as a distinct entity within the group of "DLBCL NOS". 1 This is a rare but aggressive type of cutaneous lymphoma, which predominantly affects elderly and/or immunodeficient patients. 2 However, this entity must be distinguished from EBV-positive mucocutaneous ulcers (MCU)

show abstract

“…13–16 Severe HV-like eruptions involve both sun exposed and sun protected areas, penetrate deeper, form necrotic ulcers with deep scarring and are associated with multisystem clinical abnormalities. 6, 17, 18…”

Section: Discussionmentioning

confidence: 99%